Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Source: Benzinga
- Clinical Trial Progress: Immutep's IMP761 has completed the 2.5 and 7 mg/kg dosing levels in a Phase I trial with healthy participants, demonstrating positive safety and efficacy data without serious adverse reactions, indicating its potential in treating autoimmune diseases.
- Immunosuppressive Effects: The drug exhibited dose-dependent immunosuppressive effects, achieving significant and long-lasting inhibition of T-cell-mediated intradermal reactions to a strong foreign antigen on days 2, 9, and 23, potentially offering new treatment avenues for conditions like rheumatoid arthritis.
- Market Opportunity: As a therapeutic target for autoimmune diseases, LAG-3 positions IMP761 to address large markets, including Type 1 diabetes and multiple sclerosis, which could translate into multi-billion dollar opportunities for the company.
- Future Outlook: Immutep plans to continue the trial as scheduled, with additional updates expected in the first half of 2026, further enhancing market interest and investor confidence in this promising program.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMMP is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.060
Low
12.00
Averages
12.00
High
12.00
Current: 3.060
Low
12.00
Averages
12.00
High
12.00
No data
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep's First LAG-3 Antibody Trial Shows Positive Phase I Results
- Clinical Trial Progress: Immutep's IMP761 has completed the 2.5 and 7 mg/kg dosing levels in a Phase I trial with healthy participants, demonstrating positive safety and efficacy data without serious adverse reactions, indicating its potential in treating autoimmune diseases.
- Immunosuppressive Effects: The drug exhibited dose-dependent immunosuppressive effects, achieving significant and long-lasting inhibition of T-cell-mediated intradermal reactions to a strong foreign antigen on days 2, 9, and 23, potentially offering new treatment avenues for conditions like rheumatoid arthritis.
- Market Opportunity: As a therapeutic target for autoimmune diseases, LAG-3 positions IMP761 to address large markets, including Type 1 diabetes and multiple sclerosis, which could translate into multi-billion dollar opportunities for the company.
- Future Outlook: Immutep plans to continue the trial as scheduled, with additional updates expected in the first half of 2026, further enhancing market interest and investor confidence in this promising program.
Continue Reading
ASX Penny Stocks Highlight: DUG Technology Featured Among Three Key Selections
Market Overview: Australian shares are facing challenges due to global tech sector declines, prompting investors to consider penny stocks, which may offer surprising value and stability despite their smaller size.
DUG Technology Ltd: This technology company, with a market cap of A$281.66 million, has shown improvement in financial health, reducing losses significantly over the past five years, and has potential for future growth despite current profitability challenges.
Immutep Limited: A biotechnology firm focused on immunotherapies, Immutep has a market cap of A$552.65 million and is well-positioned financially, with a strong cash position supporting ongoing clinical trials, despite being pre-revenue.
Wagners Holding Company: With a market cap of A$719.01 million, Wagners has demonstrated robust financial health and significant earnings growth, supported by its inclusion in the S&P/ASX Emerging Companies Index, although it faces challenges with long-term liabilities.
Continue Reading